Screener
Rigel Pharmaceuticals RIGL Single reportable segment — Consultants and third-party services
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept rigl:ConsultantsAndThirdPartyServicesExpense.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Commercial related expenses | 7,040 | 5,339 |
| Outside clinical trial related expenses | 6,927 | 4,371 |
| Cost of product sales | 4,606 | 4,409 |
| Consultants and third-party services | 4,006 | 3,409 |
| Other segment items | 3,352 | 3,494 |
| Interest expense, net | 228 | 1,262 |
| Provision for income taxes | 3,003 | 65 |
| Segment income | $8,654 | $11,446 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's single reportable segment — consultants and third-party services?
- Rigel Pharmaceuticals (RIGL) reported single reportable segment — consultants and third-party services of $4.01M in Q1 2026.
- What does single reportable segment — consultants and third-party services mean?
- Includes fees paid to external consultants, contractors, and service providers for specialized expertise or operational support. This metric highlights the company's reliance on external resources to supplement internal capabilities.
Ask your AI about Rigel Pharmaceuticals's single reportable segment — consultants and third-party services.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude